S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Modern Day Options Trading For Beginners! (Ad)pixel
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
Modern Day Options Trading For Beginners! (Ad)pixel
Biden's pick to lead FAA withdraws amid shaky Senate support
Travel disruption hits Germany on eve of transport strike
Modern Day Options Trading For Beginners! (Ad)pixel
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Modern Day Options Trading For Beginners! (Ad)pixel
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
Modern Day Options Trading For Beginners! (Ad)pixel
Biden's pick to lead FAA withdraws amid shaky Senate support
Travel disruption hits Germany on eve of transport strike
Modern Day Options Trading For Beginners! (Ad)pixel
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Modern Day Options Trading For Beginners! (Ad)pixel
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
Modern Day Options Trading For Beginners! (Ad)pixel
Biden's pick to lead FAA withdraws amid shaky Senate support
Travel disruption hits Germany on eve of transport strike
Modern Day Options Trading For Beginners! (Ad)pixel
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Modern Day Options Trading For Beginners! (Ad)pixel
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
Modern Day Options Trading For Beginners! (Ad)pixel
Biden's pick to lead FAA withdraws amid shaky Senate support
Travel disruption hits Germany on eve of transport strike
Modern Day Options Trading For Beginners! (Ad)pixel
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
NASDAQ:CING

Cingulate - CING Stock Forecast, Price & News

$1.03
+0.01 (+0.98%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.91
$1.03
50-Day Range
$0.91
$1.85
52-Week Range
$0.66
$2.15
Volume
50,498 shs
Average Volume
2.51 million shs
Market Capitalization
$11.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

CING stock logo

About Cingulate (NASDAQ:CING) Stock

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Receive CING Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cingulate and its competitors with MarketBeat's FREE daily newsletter.

CING Stock News Headlines

My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
Cingulate Shares Slide 19% on Stock Offering
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
Why Cingulate Shares Are Trading Higher Today
What Is the Default Mode Network?
Cingulate Pops after Positive Topline Data
Why Is Cingulate (CING) Stock Up 72% Today?
See More Headlines
Receive CING Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cingulate and its competitors with MarketBeat's FREE daily newsletter.

CING Company Calendar

Today
3/26/2023
Next Earnings (Estimated)
5/11/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CING
Fax
N/A
Employees
16
Year Founded
N/A

Profitability

Net Income
$-17,680,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.34 per share

Miscellaneous

Free Float
7,772,000
Market Cap
$11.65 million
Optionable
Not Optionable
Beta
0.06

Key Executives

  • Dr. Shane J. Schaffer Pharm.D. (Age 48)
    PharmD, CEO & Chairman
    Comp: $475k
  • Mr. Louis G. Van Horn CPA (Age 64)
    M.B.A., Exec. VP & CFO
    Comp: $380k
  • Dr. Laurie A. Myers M.B.A. (Age 66)
    Ph.D., Exec. VP & COO
    Comp: $400k
  • Mr. Craig S. Gilgallon Esq. (Age 50)
    Exec. VP, Gen. Counsel & Board Sec.
    Comp: $380k
  • Dr. Raul R. Silva M.D. (Age 65)
    Exec. VP & Chief Science Officer
  • Thomas Dalton
    Head of Investor & PR
  • Dr. Matthew N. Brams M.D. (Age 59)
    Exec. VP & Chief Medical Officer













CING Stock - Frequently Asked Questions

Should I buy or sell Cingulate stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cingulate in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CING shares.
View CING analyst ratings
or view top-rated stocks.

How have CING shares performed in 2023?

Cingulate's stock was trading at $1.00 at the beginning of 2023. Since then, CING stock has increased by 3.0% and is now trading at $1.03.
View the best growth stocks for 2023 here
.

When is Cingulate's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.
View our CING earnings forecast
.

When did Cingulate IPO?

(CING) raised $29 million in an initial public offering (IPO) on Wednesday, December 8th 2021. The company issued 4,166,666 shares at a price of $6.00-$8.00 per share.

What is Cingulate's stock symbol?

Cingulate trades on the NASDAQ under the ticker symbol "CING."

Who are Cingulate's major shareholders?

Cingulate's stock is owned by many different institutional and retail investors. Top institutional investors include HighTower Advisors LLC (0.30%). Insiders that own company stock include Craig S Gilgallon, Curtis Medeiros, Gregg Wm Givens, Horn Louis G Van, Jennifer L Callahan, Laurie Myers, Peter J Werth and Shane J Schaffer.
View institutional ownership trends
.

How do I buy shares of Cingulate?

Shares of CING stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cingulate's stock price today?

One share of CING stock can currently be purchased for approximately $1.03.

How much money does Cingulate make?

Cingulate (NASDAQ:CING) has a market capitalization of $11.65 million. The company earns $-17,680,000.00 in net income (profit) each year or ($1.57) on an earnings per share basis.

How can I contact Cingulate?

The official website for the company is www.cingulate.com. The company can be reached via phone at 913-942-2300 or via email at ir@cingulate.com.

This page (NASDAQ:CING) was last updated on 3/26/2023 by MarketBeat.com Staff